New clinical trial designs for establishing drug efficacy and safety in a precision medicine era

por Heerspink, Hiddo J. L., List, James, Perkovic, Vlado
Publicado 2018

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

por Kohan, Donald E, Fioretto, Paola, Tang, Weihua, List, James F
Publicado 2014

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

por List, James F., Woo, Vincent, Morales, Enrique, Tang, Weihua, Fiedorek, Fred T.
Publicado 2009

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA(1c), Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

por Rosenstock, Julio, Vico, Marisa, Wei, Li, Salsali, Afshin, List, James F.
Publicado 2012

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

por Ferrannini, Ele, Ramos, Silvia Jimenez, Salsali, Afshin, Tang, Weihua, List, James F.
Publicado 2010

A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment

por Wilding, John P.H., Norwood, Paul, T'joen, Caroline, Bastien, Arnaud, List, James F., Fiedorek, Fred T.
Publicado 2009

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

por Bailey, Clifford J, Gross, Jorge L, Hennicken, Delphine, Iqbal, Nayyar, Mansfield, Traci A, List, James F
Publicado 2013

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

por Bailey, Clifford J, Gross, Jorge L, Hennicken, Delphine, Iqbal, Nayyar, Mansfield, Traci A, List, James F
Publicado 2013

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

por Whaley, Jean M, Tirmenstein, Mark, Reilly, Timothy P, Poucher, Simon M, Saye, JoAnne, Parikh, Shamik, List, James F
Publicado 2012